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Abstract (233/250)
Background: The evidence base to guide pharmacological management of 
tone and abnormal movements in Cerebral Palsy (CP) is limited, as is an 
understanding of routine clinical practice in the UK. We aimed to establish 
details of motor phenotype and current pharmacological management of a 
representative cohort across a network of UK tertiary centres.
Methods: Prospective multi-centre review of specialist motor disorder clinics 
at 8 UK centres, collecting data on clinical features and pharmacological 
management of children and young people (CYP) with CP over a single 
calendar month. 
Results: Data was collected from 275 CYP with CP reviewed over the 
calendar month of October 2017.  Isolated dystonia or spasticity was 
infrequently seen, with a mixed picture of dystonia and spasticity +/- 
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choreoathetosis identified in 194/275 (70.5%) of CYP.A co-morbid diagnosis 
of epilepsy was present in 103/275 (37.4%). The most commonly used 
medications for abnormal tone/movement were baclofen, trihexyphenidyl, 
gabapentin, diazepam and clonidine. Medication use appeared to be 
influenced separately by the presence of dystonia or spasticity. Botulinum 
toxin use was common (62.2%). A smaller proportion of children (12.4%) had 
undergone a previous neurosurgical procedure for tone/movement 
management.
Conclusions:
CYP with CP frequently present with a complex movement phenotype and co-
morbid epilepsy. They have multiple therapy, medical and surgical 
management regimens. Future trials of therapeutic, pharmacological or 
surgical interventions in this population must adequately encompass this 
complexity in order to be translatable to clinical practice. 
Introduction
Cerebral Palsy (CP) is the commonest form of chronic neurodisability 
encountered in paediatric practice and may be defined as a cli ical syndrome 
of “permanent disorders of the development of movement and posture, 
causing activity limitation, that are attributed to non-progressive disturbances 
that occurred in the developing fetal or infant brain”(1). Elevated tone and 
involuntary movements are typically experienced by Children and Young 
People (CYP) with CP.  Elevated tone, or hypertonia, caused by abnormal 
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muscle contraction may be due to spasticity, dystonia, rigidity, or a variable 
combination of these pathological findings(2). The most widely adopted 
classification system for CP is the Surveillance of Cerebral Palsy in Europe 
(SCPE) classification(3), which classifies CYP on the basis of the 
Predominant Motor Type.  On this basis, 80-95% of CYP with CP are 
considered to have “spastic” CP, and 5-17% the “Dyskinetic” form (dystonia 
+/- choreoathetosis)(4, 5). One limitation of this system is that spasticity and 
dystonia are treated as mutually exclusive, when in reality they are often co-
incident in children with motor disorders(6-8).
Elevated tone and involuntary movements typically interfere with independent 
function and participation, the delivery of daily care and overall quality of life. 
Consequently, pharmacological interventions are commonly prescribed, 
though the evidence base to guide the clinician’s choice of most appropriate 
medication is currently extremely limited. The recent American Academy of 
Cerebral Palsy and Developmental Medicine (AACPDM) guidelines on the 
management of dystonia in CP concluded that ther  was insufficient evidence 
to support any oral pharmacological agent, instead basing recommendations 
entirely upon expert opinion(9). A number of recent reviews of the 
management of Dyskinetic CP have highlighted the paucity of high quality 
evidence in this patient group (9-11). The National Institute for Health and 
Care Excellence in the UK has produced guidelines for the management of 
spasticity in CYP(12), as has the Quality Standards Subcommittee of the 
American Academy of Neurology and the Practice Committee of the Child 
Neurology Society in the US(13). In both cases, a paucity of high quality 
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evidence was identified for enteral pharmacological interventions in particular.
Taken collectively, there is a pressing need for better quality evidence to 
guide the pharmacological management of CYP with CP. CP is a 
heterogeneous disorder, in terms of the nature of the underlying brain injury, 
pattern of motor difficulties, functional impairments and medical co-morbidities 
experienced. This heterogeneity creates challenges for the design of definitive 
interventional studies, as does the current limited knowledge of 
pharmacological management in current clinical practice beyond the 
recommendation of experts(14, 15).
In preparation for designing future trials of pharmacological management of 
abnormal tone and movement in CYP with CP we performed a prospective 
multi-centre review in the outpatient setting over a calendar month. We aimed 
to determine:
 The clinical characteristics of CYP with CP seen during this snap shot 
of clinical practice, focusing particularly on their pattern of motor 
abnormalities
 Current pharmacological management of abnormal tone and 
movement
 Diagnosis of co-morbid epilepsy and its management
 Determination of factors such as botulinum toxin use which could 
confound future potential enrolment in pharmacological studies.
Method
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A prospective evaluation of CYP with a clinical diagnosis of CP seen in 
tertiary paediatric neurology/neurodisability motor disorder clinics at 8 UK 
centres (Evelina London Children’s Hospital, Great Ormond Street Hospital, 
Great North Children’s Hospital, University Hospitals Bristol, Alder Hey 
Children’s Hospital, Leeds Teaching Hospital, Royal Belfast Hospital for Sick 
Children, John Radcliffe Hospital and Sheffield Children’s Hospital) was 
undertaken. Data was recorded from all cases seen over the calendar month 
October 2017, using a standardised data pro-forma. Data included details of 
gender, age, Gross Motor Classification System (GMFCS) level(16), Manual 
Ability Classification Sys em (MACS) level(17), current medication use, 
diagnosis of co-morbid epilepsy, and whether the CYP had undergone a 
neurosurgical intervention aimed at reducing tone and/or abnormal 
movements -  namely Deep Brain Stimulation (DBS), intrathecal baclofen 
(ITB) pump insertion, or Selective Dorsal Rhizotomy (SDR). The 
presence/absence of dystonia and/or spasticity was determined using the 
Hypertonia Assessment Tool (18), as outlined in Box 1. The presence of 
choreoathetosis as defined by the Taskforce for Childhood Movement 
disorder (19) was also recorded (Box 1). For all three motor abnormalities, 
clinicians were asked to record whether this was clinically significant. This 
was a subjective judgment, based on whether the recording cli ician felt that 
the motor abnormality interfered sufficiently with function and participation, 
delivery of daily cares and/or quality of life to require an intervention aimed at 
its reduction. Descriptive statistics were used to summarise the data, with 
analysis performed on SPSS Version 24.
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Results
Data was collected from a total of 275 CYP with CP (162 male), median age 9 
years (Range 1-18 years, 5 to 9 years, 25th-75th Centile).  Clinico-
demographic features are shown in Table 1. Both GMFCS (available for all 
275 cases) and MACS levels (available for 258/275 cases) demonstrated 
peaks at Level II and Level V (Figure 1(a)).  Details of motor phenotype are 
illustrated in Figure 1(b). Spasticity was identified in 242/275 (88.0%) CYP, 
judged clinically significant in 176/242 (72.7%). Dystonia was identified in 
222/275 (80.7%) CYP; this was judged to be clinically significant in 172/222, 
77.4%).  Choreoathetosis was identified in 75/275 (27.2%) CYP (clinically 
significant in 26/75 (34.6%). 
Isolated spasticity was identified in only 47/275 (17.1%) CYP, isolated 
dystonia in 16/275 (5.8%) CYP, with no CYP demonstrating isolated 
choreoathetosis. A mixture of spasticity and dystonia was identified in 132/275 
(48.0%) CYP, dystonia and choreoathetosis in 12/275 (4.4%) CYP and 
spasticity and choreoathetosis in 1/275 (0.4%) CYP. A combination of 
spasticity, dystonia and choreoathetosis was identified in 62/275 (22.5%). The 
remaining 5/275 (1.8%) CYP demonstrated no dystonia, spasticity or 
choreoathetosis.
Details of medication use are provided in Table 2. A total of 14 medications 
were identified across the cohort in use to reduce tone/abnormal movements. 
At the time of data collection, 98/275 (35.6%) CYP were receiving no 
medications for the management of abnormal tone/movement, 97/275 
(35.3%) CYP 1 medication, 42/275 (15.3%) CYP 2 medications, 23/275 
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(8.4%) CYP 3 medications, 12/275 (4.4%) CYP 4 medications and 3/275 
(1.1%) CYP 5 medications.
The most commonly used medications were baclofen (108/275, 39.3%), 
trihexyphenidyl (56/275, 20.4%), gabapentin (51/275, 18.5%), diazepam 
(36/275, 13.1%) and clonidine (28/275, 10.2%). Choice of medication 
appeared to differ depending upon whether clinically significant spasticity or 
dystonia was noted in the CYP (Figure 2). The use of baclofen did not seem 
to be significantly altered by the presence or absence of dystonia, but 
trihexyphenidyl, gabapentin and clonidine were all infrequently used when 
dystonia was not present (Figure 2(a)). Conversely, the presence of clinically 
significant spasticity seemed to increase the use of baclofen, but have 
minimal impact on the use of trihexyphenidyl, gabapentin or clonidine (Figure 
2(b)). Diazepam use also did not seem to differ with the presence of clinically 
significant spasticity.
In addition to enteral medications for the managem nt of abnormal 
tone/movements, 171/275 (62.2%) CYP were receiving botulinum toxin 
injections as part of their overall management.
An additional diagnosis of epilepsy had been made in 104/275 (37.4%) of 
CYP, with 68/104 (65.4%) receiving 1 Anti-Epileptic Drug (AED) and 27/104 
(26.0%) 2 or more AEDs. A total of 16 different AEDs were identified, with the 
most commonly used being sodium valproate (51/275, 18.5%). In one case, 
the ketogenic diet was being used to manage epilepsy.
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A total of 34/275 (12.4%) CYP had undergone a neurosurgical procedure – 3 
DBS, 6 SDR, and 25 ITB.
Discussion
CP is a common condition, likely to be encountered frequently by 
professionals working across all settings in acute and community paediatrics. 
Despite this, at present a higher level of evidence exists to support the use of 
invasive neurosurgical interventions to manage tone, suitable for only a 
minority of CYP(9) compared to evidence for enteral medications, which are 
prescribed frequently for the majority of this patient group. 
The data from this multi-centre prospective case review has demonstrated the 
complexity and variability of the motor phenotype, pharmacological 
management and associated co-morbidities of CYP with CP, illustrating the 
challenges in performing definitive trials of pharmacological intervention in this 
population. Data has been collected from tertiary care (specialist) clinics, and 
we believe is representative of practice in this setting in UK. Clinicians 
working in Paediatric tertiary care typically guide and advice the management 
of CYP by Secondary and Primary care teams (with active co-management of 
many CYP), and so our data is also likely to be applicable in these settings.
CYP with CP are commonly categorized on the basis of their predominant 
motor difficulty into “spastic”, “dyskinetic” or “ataxic” forms. This is an overly 
reductive approach, as in clinical practice a mixed picture is generally seen, 
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as underlined by our finding that 70.5% of CYP presented with dystonia and 
spasticity (+/- choreoathetosis). Isolated dystonia or spasticity was relatively 
infrequently seen. Ataxic cerebral palsy is very rare, and potentially over-
reported(20). This is consistent with the findings of Rice and Colleagues, who 
identified frequent dystonia in a cohort of 129 CYP with “spastic” CP(7). If the 
results of future interventional studies are to be translatable into clinical 
practice, they must be undertaken in children with a representative picture of 
mixed tone/abnormal movements.  
The HAT is a validated means of defining whether spasticity and/or dystonia 
are present in a child(18). No such tool exists for choreoathetosis, though the 
recently developed Dyskinesia Impairment Scale does provide a tool for the 
measurement of choreoathetosis separate from dystonia(21). The definitions 
of both chorea and athetosis proposed by the SCPE(22) are very similar to 
those proposed by the Taskforce on Childhood Movement Disorders(19), but 
challenges with the practical recognition of these movements have been 
raised(23). It is of note in our study the relatively infrequent recognition of 
choreoathetosis compared to dystonia, with 2/7 centres documenting no CYP 
with these abnormal movements over a calendar month. Further work is likely 
to be required prior to future multi-centre interventional studies to ensure the 
validity and reliability of the recognition of choreoathetosis between 
investigators.
Measuring the extent/severity of dystonia, spasticity and choreoathetosis in 
CYP is challenging, and generally relies upon the application of clinically 
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applied scales. A recent review of available scales for dystonia and 
choreoathetosis in children with Dyskinetic Cerebral Palsy identified 
significant limitations, not least of which was that they have been designed to 
classify movement disorders at the level of body function and structures, 
rather than activity or participation(24). Similarly, the measurement of 
spasticity in the clinical setting is challenging (25-27). Put simply, there is no 
“perfect” tool to measure these different motor abnormalities directly, and 
measuring a reduction of these symptoms in isolation would fail to capture the 
true impact of an intervention for CYP and their families and carers(28).
A wide range of medications were identified in the management of abnormal 
tone and movement in this cohort, with the presence of spasticity and 
dystonia appearing to separately influence the choice of medication. There is 
very limited data available regarding current clinical practice for prescribing of 
medications for the management of abnormal tone and movement in CP or in 
other childhood conditions. In a retrospective analysis of 278 CYP in the UK 
with dystonia of different aetiology, the most commonly used medications 
were baclofen, trihexyphenidyl, levodopa and diazepam(15). In a prospective 
study of the management of dystonia in 57 CYP with CP at a tertiary care 
centre in Australia, baclofen and gabapentin were the most commonly used 
oral medications(14). Baclofen is a Gamma-aminobutyric acid (GABA) B 
receptor agonist, and data from our presented study confirms its widespread 
use in the management of hypertonia in childhood. Despite this widespread 
use, evidence for its efficacy is extremely limited. Recent systematic reviews 
of oral pharmacological management of dystonia in CP found no studies of 
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baclofen meeting their inclusion criteria (9, 11). Evidence to support the use of 
oral baclofen (in contrast to intrathecal baclofen) in the management of 
spasticity is currently limited, with contradictory findings reported(13). 
Trihexyphenidyl, a centrally acting anti-cholinergic agent, has no role in the 
management of spasticity. A larger number of studies have examined the 
efficacy of trihexyphenidyl in the management of dystonia in CP, but results to 
date have been contradictory(9, 11).  Whilst sufficient evidence was identified 
for the AAN guidelines to recommend the short-term use of diazepam (which 
potentiates the post-synaptic inhibitory effect of GABA) to reduce 
spasticity(13), longer term use for the management of spasticity and for 
reduction of dystonia is currently lacking(9, 11, 13). Gabapentin (an analogue 
of GABA) appears to be an increasingly used medication for tone reduction in 
CP, but published data is very limited. A retrospective study of gabapentin in 
69 children with dystonia (Level 4 evidence), including 25 with CP reported 
perceived benefits(29). Similarly, the use of clonidine (a centrally acting alpha-
adrenergic agonist) in the management of hypertonicity in childhood appears 
to becoming more common, but published data supporting this use is limited 
to isolated case reports, and a single retrospective study of 33 children with 
dystonia of varied aetiology (level 4 evidence)(11, 30). Gabapentin is a widely 
used medication for the management of neuropathic pain. It remains to be 
determined to what extent its use in CYP is focused primarily on reduction of 
pain, as opposed to a primary intention to reduce elevated tone and posturing 
(though these two aims are not entirely distinct). Given the limited efficacy of 
baclofen and trihexyphenydil experienced anecdotally in many CYP with high 
tone in CP, the growing use of gabapentin and clonidine is likely to reflect a 
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pragmatic approach by clinicians to exploring medications with established 
indications and safety profiles for new indications.
Further adding to the complexity of management in these CYP was the 
comorbid diagnosis of epilepsy in almost 40%, the use of botulinum toxin in 
62.2%, and a previous neurosurgical intervention in 12.4%.  Epilepsy is a 
common co-morbidity in CP, with data from the SCPE network from 1976-
1998 reporting an overall incidence of 35% of CYP.(31). Higher rates of 
epilepsy were identified in CYP with dyskinetic or bilateral spastic CP. Many 
medications used primarily for the management of epilepsy may have a 
potentially beneficial effect on choreoathetoid movements (e.g. 
carbamazepine, levetiracetam)(11), posing further potential confounding 
factors for future definitive studies of interventions aimed at reducing 
abnormal tone and movements in this population. Additionally, the potential 
exists for AED medications to interact adversely with medications aimed at 
reducing tone and movement, in terms of drug metabolism and the risk of 
potentiating side effects (e.g. sedation/respiratory d pression when baclofen 
and clobazam are used together). 
A number of limitations must be acknowledged to our presented study. Firstly, 
motor phenotype was reported by each individual centre, with no measure of 
reliability or reproducibility of this assessment between centres. This is 
particularly pertinent given that 2/7 centres identified no choreoathetosis in the 
CYP reported. The determination of whether identified motor abnormalities 
were clinically significant was subjective, and, as such, subject to the biases 
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of the individual clinicians. Data was collected on current medication use, but 
no data was recorded on doses (units/kg), perceived or measured efficacy, 
side effects, or previous medication use. No data was collected on the clinical 
reasoning guiding medication choices for the CYP reviewed. Additionally, data 
was not collected around therapeutic interventions, orthoses, and broader 
non-neurological medical co-morbidities. 
Conclusion:
This study highlights that CYP with CP represent a complex patient group, 
with a typically mixed-motor phenotype, and often multi-modal methods of 
management of abnormal tone and movements. A large number of 
medications are in current use for the management of these motor difficulties, 
most commonly baclofen and trihexyphenidyl. Currently, only very limited 
evidence is available to support the efficacy of these medications, 
There is a pressing need for definitive studies to guide clinical practice, but 
intelligent and pragmatic trial design is required. Trial design must also 
accommodate co-morbid epilepsy, in addition to wider medical co-morbidities. 
It must consider confounding interventions, including therapeutic and non-
pharmacological treatments. There must be multi-stakeholder engagement, to 
include CYP, Parents, allied health professionals, medical and surgical 
clinicians. A priority list is required to enable a collaborative approach which 
will enable the clinical research community to move forward as a whole to 
address this function, addressing outcomes across different levels of function, 
across all domains of the ICF (some provisional suggestions for which are 
outlined in Box 2). It is imperative that the design of future trials encompasses 
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these complexities to allow their outputs to directly inform clinical practice, and 
lead to tangible improvements in quality of life for CYP with CP.
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What is already known on this topic:
3 – 25 words each
Cerebral palsy is the most common diagnosis in children who present with 
hypertonia; they present with a mixed pattern of tone and movement 
abnormalities.
Despite widespread use of medications for tone management, there is little 
evidence to inform best practice in pharmacological management of 
hypertonia in this population.
Research design is limited by the complexity of presentation: the definition of 
the population, confounding co-morbidities interventions and lack of robust 
outcome measures.
What this paper adds:
Page 15 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
2 – 25 words each
This paper reports the described motor phenotype of CYP with CP presenting 
to specialist neurodisability services in the UK.
It is the first paper to report current prescribing practice for this population, 
and highlights the multiple medications used for tone management.
It highlights the prevalence of epilepsy as a co-morbidity, with anti-convulsant 
medication prescription, and confounding medical and surgical interventions 
which may affect tone management.
References:1. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8-142. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. 
Pediatrics. 2003;111:e89-97 3. Prevalence and characteristics of children with cerebral palsy in Europe. 
Dev Med Child Neurol. 2002;44:633-404. Sellier E, Platt MJ, Andersen GL, Krageloh-Mann I, De La Cruz J, Cans C. Decreasing prevalence in cerebral palsy: a multi-site European population-based study, 1980 to 2003. Dev Med Child Neurol. 2016;58:85-925. Smithers-Sheedy H, McIntyre S, Gibson C, et al. A special supplement: findings from the Australian Cerebral Palsy Register, birth years 1993 to 2006. 
Dev Med Child Neurol. 2016;58 Suppl 2:5-106. Howard J, Soo B, Graham HK, et al. Cerebral palsy in Victoria: motor types, topography and gross motor function. J Paediatr Child Health. 2005;41:479-837. Rice J, Skuza P, Baker F, Russo R, Fehlings D. Identification and measurement of dystonia in cerebral palsy. Dev Med Child Neurol. 2017;59:1249-558. Lin JP, Lumsden DE, Gimeno H, Kaminska M. The impact and prognosis for dystonia in childhood including dystonic cerebral palsy: a clinical and demographic tertiary cohort study. J Neurol Neurosurg Psychiatry. 2014;85:1239-44 9. Fehlings D, Brown L, Harvey A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev 
Med Child Neurol. 2018;60:356-66 
Page 16 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
10. Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol. 2017;16:741-9 11. Masson R, Pagliano E, Baranello G. Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review. Dev Med Child 
Neurol. 2017;59:1237-48 12. Excellence NIfHaC. Spasticity in children and young people with non-progressive brain disorders: Management of spasticity and co-existing motor disorders and their early musculoskeletal complications. London: National Institute for Health and Care Excellence; 2012.13. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:336-43 14. Harvey A, Reddihough D, Scheinberg A, Williams K. Oral medication prescription practices of tertiary-based specialists for dystonia in children with cerebral palsy. J Paediatr Child Health. 2018;54:401-4
15. Lumsden DE, M.; Tomlin, S.; Lin, J-P. Medication Use in Chilhood Dystonia. 
Eur J Paediatr Neurol. 2016 Jul;20(4):625-916. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-23 17. Eliasson AC, Krumlinde-Sundholm L, Rosblad B, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006;48:549-54 18. Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol. 2010;52:e83-719. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25:1538-4920. Smithers-Sheedy H, Badawi N, Blair E, et al. What constitutes cerebral palsy in the twenty-first century? Dev Med Child Neurol. 2014;56:323-821. Monbaliu E, Ortibus E, De Cat J, et al. The Dyskinesia Impairment Scale: a new instrument to measure dystonia and choreoathetosis in dyskinetic cerebral palsy. Dev Med Child Neurol. 2012;54:278-8322. Christine C, Dolk H, Platt MJ, Colver A, Prasauskiene A, Krageloh-Mann I. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. Dev Med Child Neurol Suppl. 2007;109:35-8 23. Eggink H, Kremer D, Brouwer OF, et al. Spasticity, dyskinesia and ataxia in cerebral palsy: Are we sure we can differentiate them? Eur J Paediatric Neurol  2017;21:703-6 24. Stewart K, Harvey A, Johnston LM. A systematic review of scales to measure dystonia and choreoathetosis in children with dyskinetic cerebral palsy. 
Dev Med Child Neurol. 2017;59:786-9525. Love S, Gibson N, Smith N, Bear N, Blair E. Interobserver reliability of the Australian Spasticity Assessment Scale (ASAS). Dev Med Child Neurol. 2016;58 
Suppl 2:18-24 
Page 17 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
26. Scholtes VA, Becher JG, Beelen A, Lankhorst GJ. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. Dev Med Child Neurol. 2006;48:64-7327. Flamand VH, Masse-Alarie H, Schneider C. Psychometric evidence of spasticity measurement tools in cerebral palsy children and adolescents: a systematic review. J Rehabil Med. 2013;45:14-2328. Lumsden DE, Gimeno H, Tustin K, Kaminska M, Lin JP. Interventional studies in childhood dystonia do not address the concerns of children and their carers. Eur J Paediatr Neurol 2015;19:327-3629. Liow NY, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol 2016;20:100-7
30. Sayer C, Lumsden DE, Kaminska M, Lin JP. Clonidine use in the outpatient 
management of severe secondary dystonia. Eur J Paediatr Neurol 2017 21(4):621-
62631. Sellier E, Uldall P, Calado E, et al. Epilepsy and cerebral palsy: characteristics and trends in children born in 1976-1998. Eur J Paediatr Neurol 2012;16:48-55
Page 18 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Tables:
Level Number % Cohort
I 35 12.7
II 51 18.5
III 24 8.7
IV 70 25.5
GMFCS
V 95 34.5
I 37 13.5
II 70 25.4
III 32 11.6
IV 48 17.5
MACS
V 71 25.8
None 53 19.3
Not Significant 50 18.2
Dystonia
Clinically Significant 172 62.5
None 33 12.0
Not Significant 66 24.0
Spasticity
Clinically Significant 176 64.0
None 200 72.7
Not Significant 49 17.8
Choreoathetosis
Clinically Significant 26 9.5
Yes 104 37.8Epilepsy
No 171 62.2
Yes 171 62.2Botulinum Toxin 
Program No 104 37.8
Yes 3 1.1Deep Brain 
Stimulation No 272 98.9
Yes 25 9.1Intrathecal 
Baclofen No 250 90.9
Yes 6 3.2Selective Dorsal 
Rhizotomy No 269 97.8
Table 1: Clinical Features of CYP with CP reviewed in clinic. 
Abbreviations used: “GMFCS” – Gross Motor Classification System, “MACS” 
– Manual Ability Classification System.
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Medications Type Medication Number % Overall 
cohort
Baclofen 108 39.3
Trihexyphenidyl 56 20.4
Gabapentin 51 18.5
Diazepam 36 13.1
Clonidine 28 10.2
Chloral Hydrate 11 4.0
Levodopa 9 3.3
Nitrazepam 2 0.7
Clonazepam 2 0.7
Midazolam 1 0.4
Risperidone 1 0.4
Nabiximol 1 0.4
Amitriptyline 1 0.4
Tone/Movement 
Tizanidine 1 0.4
Sodium Valproate 51 18.5
Levetiracetam 23 8.4
Carbamazepine 19 6.9
Lamotrigine 11 4.1
Topiramate 10 3.6
Clobazam 3 1.1
Nitrazepam 2 0.7
Oxcarbazepine 2 0.7
Lacosamide 2 0.7
Vigabatrin 1 0.4
Clonazepam 1 0.4
Phenytoin 1 0.4
Epilepsy
Phenobarbitone 1 0.4
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Zonisamide 1 0.4
Calcium Folinate 1 0.4
Perampanel 1 0.4
Table 2: Medication Use across the cohort.
Figure Legends
Figure 1:
1(a) Distribution of Gross Motor Function Classification System (GMFCS) and 
Manual Ability Classification System (MACS) levels across the cohort.1(b) 
Motor phenotype of CYP in the cohort, with presence of spasticity 
and/dystonia defined as per the Hypertonia Assessment Tool (HAT) and 
choreoathetosis as defined by the Taskforce on Childhood Motor disorders. 
Clinical significance of these features was based on judgment of the reporting 
clinicians.
Figure 2:
Frequency of individual medication use depending upon whether CYP 
demonstrated clinically significant (a) Dystonia, (b) Spasticity or (c) 
Choreoathetosis.
Page 21 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Box 1
Spasticity Features denoting presence of spasticity according to 
Hypertonia Assessment Tool(10)
 Velocity‐dependent resistance to stretch
 Presence of spastic catch
Dystonia Features denoting presence of dystonia according to 
Hypertonia Assessment Tool (10)
 Increased involuntary movements or postures of 
the designated limb with tactile stimulus of a 
distant body part
 Increased involuntary movements or postures with 
purposeful movement of a distant body part
 Increased tone with movement of a distant body 
part
Choreoathetosis As defined by the Taskforce on Childhood Movement 
Disorders (19)
Chorea is an ongoing random-appearing sequence of 
one or more discrete involuntary movements or 
movement fragments. 
Athetosis is a slow, continuous, involuntary writhing 
movement that prevents maintenance of a stable posture
Box 2
Priorities to be addressed for development of future trial design of 
medications for the treatment of tone and movement in CP
 How to standardize a description of the motor profile of children with 
CP?
 How to ensure the reliability of motor phenotyping across multiple 
centres and clinicians?
Page 22 of 25
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 Accepting a single trial cannot include all children and young people 
with CP. How should this heterogenous cohort be divided into 
biologically and clinically meaningful studies for future trial designs 
(e.g by functional level, age, aetiology, features of motor 
phenotype)?
 What Outcome measures should be used? Measures must map 
across all domains of the ICF, and be meaningful to children and 
young people with CP, their parents/carers and clinicians alike?
 Over what time scale should studies be performed?
 What medications should be trialed, and compared to what? Would a 
placebo arm be acceptable to children and young people with CP, 
their parents/carers and clinicians alike? What medication would be 
considered the “standard of care”?
 Given the off license use of most medications in current clinical 
practice, what dosing range and schedules should be used for 
medications included in future pharmacological studies?
 To what extent can other aspects of care be standardized during the 
time children and young people with CP are enrolled in future studies 
(e.g. application of orthoses)?
 Should future trials focus on medication naïve children and young 
people? This would simplify study design, but would limit recruitment, 
preventing many children and young people with CP benefitting from 
and contributing to trial enrollment.
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Figure 1: 
1(a) Distribution of Gross Motor Function Classification System (GMFCS) and Manual Ability Classification 
System (MACS) levels across the cohort.1(b) Motor phenotype of CYP in the cohort, with presence of 
spasticity and/dystonia defined as per the Hypertonia Assessment Tool (HAT) and choreoathetosis as defined 
by the Taskforce on Childhood Motor disorders. Clinical significance of these features was based on 
judgment of the reporting clinicians. 
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Figure 2: 
Frequency of individual medication use depending upon whether CYP demonstrated clinically significant (a) 
Dystonia, (b) Spasticity or (c) Choreoathetosis. 
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